Azithromycin News and Research

RSS
Azithromycin, also known as Zithromax, belongs to the class of medicines known as antibacterials orantibiotics. These medicines kill bacteria (small organisms that can cause infection in humans) or stopbacteria from growing. Patients with weakened immune systems, includingpeople with HIV, tend to have more frequent andmore serious bacterial infections. Azithromycinwas approved by the FDA on June 14, 1996, formany uses, including the prevention and treatmentof Mycobacterium avium complex (MAC) inpersons with advanced HIV infection. It is alsobeing investigated to see how well it works inpreventing other kinds of bacterial infections inpeople with HIV.
Growing concerns about drug resistance highlight importance of preventing gonorrhea infection

Growing concerns about drug resistance highlight importance of preventing gonorrhea infection

Gonorrhoea infections increase across Europe

Gonorrhoea infections increase across Europe

Azithromycin remains effective in treatment of urogenital chlamydia, confirms UAB study

Azithromycin remains effective in treatment of urogenital chlamydia, confirms UAB study

Use of azithromycin early reduces risk of recurrent, severe LRTI among young children

Use of azithromycin early reduces risk of recurrent, severe LRTI among young children

Giving antibiotics early can reduce risk of severe lower respiratory tract illness in children

Giving antibiotics early can reduce risk of severe lower respiratory tract illness in children

Antibiotics have no adverse outcome on child's physical development, shows study

Antibiotics have no adverse outcome on child's physical development, shows study

Researchers to present case report of acute inhalation lung injury related to use of e-cigarettes

Researchers to present case report of acute inhalation lung injury related to use of e-cigarettes

Common antibiotic azithromycin effectively kills many multidrug-resistant bacteria

Common antibiotic azithromycin effectively kills many multidrug-resistant bacteria

First randomized, controlled trial of pharmacotherapy in PCD patients now in place

First randomized, controlled trial of pharmacotherapy in PCD patients now in place

Case Western Reserve professor urges action to eliminate yaws

Case Western Reserve professor urges action to eliminate yaws

Manchester researcher discover novel way to eradicate cancer stem cells

Manchester researcher discover novel way to eradicate cancer stem cells

SLU researcher discovers new information about how antibiotics stop staph infections

SLU researcher discovers new information about how antibiotics stop staph infections

Tianyin Pharmaceutical releases unaudited preliminary financial results for Q1 FY 2015

Tianyin Pharmaceutical releases unaudited preliminary financial results for Q1 FY 2015

Current recommendations advise prompt antiviral treatment for high-risk patients with influenza

Current recommendations advise prompt antiviral treatment for high-risk patients with influenza

Pneumonia patients treated with azithromycin face lower risk of death, slightly increased risk of heart attack

Pneumonia patients treated with azithromycin face lower risk of death, slightly increased risk of heart attack

Review on effects of treating cholera with antimicrobial drugs

Review on effects of treating cholera with antimicrobial drugs

InSite and Senju collaborate to develop and market azithromycin ophthalmic solution using DuraSite

InSite and Senju collaborate to develop and market azithromycin ophthalmic solution using DuraSite

TPI announces financial results for second quarter fiscal year 2014

TPI announces financial results for second quarter fiscal year 2014

Researchers identify potential therapy for meibomian gland dysfunction

Researchers identify potential therapy for meibomian gland dysfunction

TPI’s revenue decreases 8.1% to $14.8 million in first quarter fiscal year 2014

TPI’s revenue decreases 8.1% to $14.8 million in first quarter fiscal year 2014

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.